Warfarin prophylaxis in patients with nonvalvular atrial fibrillation may be one of the most valuable public-health interventions. Barriers to its optimal utilization include wariness about bleeding complications and concern about age-related sensitivity to the drug. The risks, however, may be minimized by creation of anticoagulation clinics to ensure optimal dosing and follow-up.